The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics

David C. Wheeler(University College London), Hiddo J.L. Heerspink(University Medical Center Groningen), Robert D. Toto(Southwestern Medical Center), Shin‐Wook Kang(Yonsei University), Anna Maria Langkilde(AstraZeneca (Sweden)), Frederik Persson, Naoki Kashihara(Kawasaki Medical School), Tom Greene(University Medical Center Groningen), Rey Isidto, Walter Douthat, Kausik Umanath(Wayne State University), Magnus Lindberg(University of Gävle), Fan Fan Hou(Southern Medical University), John J.V. McMurray(University of Glasgow), István Wittmann(FIND), David Z.I. Cherney(University Health Network), Glenn M. Chertow(Stanford Health Care), Dinesh Khullar(Max Super Speciality Hospital), Roberto Pecoits‐Filho(Pontifícia Universidade Católica do Paraná), C. David Sjöström(University Medical Center Groningen), Patrick B. Mark(Queen Elizabeth University Hospital), Michał Nowicki(Medical University of Lodz), José Luis Górriz(Universitat de València), Ricardo Correa‐Rotter(University Medical Center Groningen), Hans Furuland(Uppsala University Hospital), Pham Van Bui(Cho Ray Hospital), Jamie P. Dwyer(University of Utah), Bergur V. Stefánsson(University Medical Center Groningen), Peter Rossing(Steno Diabetes Centers), М. М. Батюшин(Rostov State Medical University), Oleksandr Bilchenko(Kharkiv Medical Academy of Postgraduate Education), Elizabeth Escudero, Hermann Haller(Medizinische Hochschule Hannover)
Nephrology Dialysis Transplantation
August 10, 2020
Cited by 189


Related Papers